A Physicochemical Stability Study of Pembrolizumab Vial Leftovers: Let Us Stop Pouring Good Money Down the Drain
Open Access
Abstract
Background: Pembrolizumab is a monoclonal antibody (mAb) approved for treating Non-Small Cell Lung Cancer (NSCLC), melanoma and lymphomas. Commercialized in single-size (100 mg/4 mL) vials, the pembrolizumab solution contains no preservative. As such, the manufacturer recommends using pembrolizumab vials only once, and thus, to rapidly dispose of any unused portion. Thus, appreciable amounts of this costly product are wasted. Objective: To evaluate the physical, chemical and microbiological stability of pembrolizumab vial leftovers stored at room temperature or at 4 °C, 7 and 14 days after first vial puncturing. Methods: Following pH assessments, submicronic aggregation and turbidity of pembrolizumab were measured by dynamic light scattering (DLS) and spectrophotometry, respectively. In addition, SE-HPLC (size-exclusion high-performance liquid chromatography), IEX-HPLC (ion exchange HPLC) and peptide mapping HPLC served to respectively evaluate aggregation and fragmentation, distribution of charge and primary structure of pembrolizumab. Incubation at 37 °C for 48 h of pembrolizumab vial leftovers on blood agar plates was used to determine their microbiological stability. Results: Physical, chemical and microbiological stability of pembrolizumab leftovers was demonstrated for at least two full weeks. Conclusions: These results argue forcefully in favor of allowing prolongation of pembrolizumab vial leftovers usage well beyond a single day.Keywords
Funding Information
- Department of Pharmacy and the Foundation of the Quebec Heart & Lung Institute—Laval University
- Fonds de recherche du Quebec-Sante (FRQ-S)
This publication has 25 references indexed in Scilit:
- Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody bindingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2023
- Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?Journal of Pharmaceutical Sciences, 2023
- Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial SizesApplied Health Economics and Health Policy, 2018
- Stability of infliximab solutions in different temperature and dilution conditionsJournal of Pharmaceutical and Biomedical Analysis, 2018
- Protocols for the analytical characterization of therapeutic monoclonal antibodies. II – Enzymatic and chemical sample preparationJournal of Chromatography B, 2017
- Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residuesEuropean Journal of Cancer, 2016
- Long-term physico-chemical stability of diluted trastuzumabInternational Journal of Pharmaceutics, 2013
- Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administrationAnnales Pharmaceutiques Françaises, 2012
- Survival of Staphylococcus and other bacteria in skin prick test antigens solutionsAmerican Journal of Infection Control, 2009
- Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperatureJournal of Chromatography B, 2006